- Email: [email protected]
4485038 Method for the production and purification of human leukocyte interferon
ll6
PATENT ABSTRACTS
4485038
4485086
METHOD FOR THE PRODUCTION AND PURIFICATION OF HUMAN LEUKOCYTE INTERFERON
RADIOLABELED TUMOR IMAGING AGENT AND METHOD OF PREPARATION Dennis W Wong
Kailasb C Chadha, Eugene Sulkowski assigned to Health Research (Roswell Park Division) A process for the production and purification of human interferon derived from leukocyte of lymphoblastoid cell origin characterized by a sequence of steps involving chromatography of a solution of crude interferon on porous glass, utilizing three new classes of eluants for recovering the interferon bound to the porous glass, followed by cation exchange chromatography and finally chromatography on a hydrophobic sorbent material which process produces a final purified interferon in its natural form containing those protein components which are normally labile to low pH treatment along with those components which are pH stable. In one aspect, the improved method of purification also includes the optional molecular filtration of the crude interferon prior to initiating the purification process. In yet another embodiment, a new process for producing crude interferon from buffy coat cells utilizing a starchgel agglomeration and sedimentation technique is also described.
A novel chemical method of labeling porphyrin compounds, specifically hematoporphyrin derivative (HPD), with the radionuclide 111 In or 113rain producing a radioactive tracer material suitable for biomedical applications. HPD labeled with 111 In or 113rain is biologically act rive in vivo and is preferentially taken up by tumors. This provides a simple and specific means of localizing and detecting neoplasms in man or in animal by scintigraphic imaging techniques.
4485100 ELASTASE INHIBITORS, A PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE INHIBITORS Karl Hochstrasser, Elmar Wachter, Seefeld Oberalting, Federal Republic Of Germany assigned to Bayer Aktiengesellschaft
4485054 METHOD OF ENCAPSULATING BIOLOGICALLY ACTIVE MATERIALS IN MULTILAMELLAR LIPID VESICLES (MLV)
The invention relates to elastase inhibitors from bovine serum identified herein as BI-I-E and BIl-E+. Said inhibitors are peptides of the specified amino acid sequence defined herein and they are useful, inter alia, for the treatment of shock, rheumatoid arthritis or pulmonary emphysemia.
Michae Mezei, Fredric Nugent, Halifax, Canada assigned to Lipoderm Pharmaceuticals Limited This invention provides an improved procedure for producing large multilamellar lipid vesicles (MLV), which may be used to encapsulate a biologically active material, particularly lipophilic substances. According to this invention, a lipid film is formed on inert, solid contact masses within a vessel, by evaporating an organic solvent therefrom. Subsequent agitation in the presence of an aqueous liquid, followed by a period in which the vessel remains undisturbed yields the multilamellar vesicles. The procedure permits the encapsulation of both hydrophilic and lipophilic materials.
4485174 HEMOGLOBIN-BASED BLOOD GAS CONTROL Ching Chiang, Susan K Bolton assigned to Instrumentation Laboratory Inc Blood gas control containing hemoglobin, a pH buffering agent, and a reduced pyridine nucleotide capable of participating in a reaction which reduces methemoglobin to normal hemoglobin.
PATENT ABSTRACTS
4485038
4485086
METHOD FOR THE PRODUCTION AND PURIFICATION OF HUMAN LEUKOCYTE INTERFERON
RADIOLABELED TUMOR IMAGING AGENT AND METHOD OF PREPARATION Dennis W Wong
Kailasb C Chadha, Eugene Sulkowski assigned to Health Research (Roswell Park Division) A process for the production and purification of human interferon derived from leukocyte of lymphoblastoid cell origin characterized by a sequence of steps involving chromatography of a solution of crude interferon on porous glass, utilizing three new classes of eluants for recovering the interferon bound to the porous glass, followed by cation exchange chromatography and finally chromatography on a hydrophobic sorbent material which process produces a final purified interferon in its natural form containing those protein components which are normally labile to low pH treatment along with those components which are pH stable. In one aspect, the improved method of purification also includes the optional molecular filtration of the crude interferon prior to initiating the purification process. In yet another embodiment, a new process for producing crude interferon from buffy coat cells utilizing a starchgel agglomeration and sedimentation technique is also described.
A novel chemical method of labeling porphyrin compounds, specifically hematoporphyrin derivative (HPD), with the radionuclide 111 In or 113rain producing a radioactive tracer material suitable for biomedical applications. HPD labeled with 111 In or 113rain is biologically act rive in vivo and is preferentially taken up by tumors. This provides a simple and specific means of localizing and detecting neoplasms in man or in animal by scintigraphic imaging techniques.
4485100 ELASTASE INHIBITORS, A PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE INHIBITORS Karl Hochstrasser, Elmar Wachter, Seefeld Oberalting, Federal Republic Of Germany assigned to Bayer Aktiengesellschaft
4485054 METHOD OF ENCAPSULATING BIOLOGICALLY ACTIVE MATERIALS IN MULTILAMELLAR LIPID VESICLES (MLV)
The invention relates to elastase inhibitors from bovine serum identified herein as BI-I-E and BIl-E+. Said inhibitors are peptides of the specified amino acid sequence defined herein and they are useful, inter alia, for the treatment of shock, rheumatoid arthritis or pulmonary emphysemia.
Michae Mezei, Fredric Nugent, Halifax, Canada assigned to Lipoderm Pharmaceuticals Limited This invention provides an improved procedure for producing large multilamellar lipid vesicles (MLV), which may be used to encapsulate a biologically active material, particularly lipophilic substances. According to this invention, a lipid film is formed on inert, solid contact masses within a vessel, by evaporating an organic solvent therefrom. Subsequent agitation in the presence of an aqueous liquid, followed by a period in which the vessel remains undisturbed yields the multilamellar vesicles. The procedure permits the encapsulation of both hydrophilic and lipophilic materials.
4485174 HEMOGLOBIN-BASED BLOOD GAS CONTROL Ching Chiang, Susan K Bolton assigned to Instrumentation Laboratory Inc Blood gas control containing hemoglobin, a pH buffering agent, and a reduced pyridine nucleotide capable of participating in a reaction which reduces methemoglobin to normal hemoglobin.